My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Merck & Co (NY:MRK)

120.23 +0.92 (+0.77%)

Streaming Delayed Price Updated: 1:28 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Why Pharma and Biotech Stocks Got Thrashed on Tuesday ↗

March 25, 2025

Via The Motley Fool

What's going on in today's session: S&P500 movers ↗

March 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Tuesday's session: top gainers and losers in the S&P500 index ↗

March 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed ↗

March 25, 2025

The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved.

Via Stocktwits

Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment ↗

March 25, 2025

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

Via Benzinga

Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges ↗

March 25, 2025

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.

Via Benzinga

Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

March 25, 2025

From Merck & Co., Inc.

Via Business Wire

Analyst Initiates Coverage On 'Undervalued' Summit Therapeutics ↗

March 24, 2025

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.

Via Benzinga

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

March 24, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Which S&P500 stocks are gapping on Monday? ↗

March 24, 2025

Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

MERCK & CO., INC. (NYSE: MRK) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Merck & Co., Inc. Investors of Upcoming Deadline

March 24, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

1 Value Stock with Solid Fundamentals and 2 to Turn Down

March 24, 2025

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

March 23, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

2 Beaten-Down Stocks to Buy on the Dip ↗

March 22, 2025

Via The Motley Fool

“We’re In A Stock Pickers Market” ↗

March 22, 2025

Markets have been oscillating up and down for weeks, creating what resembles a sine wave pattern. As the analyst notes,

Via Talk Markets

Topics ETFs

Which Is The Healthiest Investment: Merck Or Pfizer ↗

March 21, 2025

Adeep dive into Merck and Pfizer, two of the biggest pharmaceutical companies out there.

Via Talk Markets

Topics Stocks / Equities

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm

March 20, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

March 20, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

March 19, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease

March 19, 2025

From Merck & Co., Inc.

Via Business Wire

Merck & Co's Options: A Look at What the Big Money is Thinking ↗

March 18, 2025

Via Benzinga

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types ↗

March 17, 2025

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.

Via Benzinga

Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. ↗

March 17, 2025

Balancing Dividends and Fundamentals: The Case of MERCK & CO. INC. (NYSE:MRK).

Via Chartmill

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

March 16, 2025

Via The Motley Fool

Topics Stocks

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.

March 15, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

A Closer Look at Merck & Co's Options Market Dynamics ↗

March 14, 2025

Via Benzinga

These S&P500 stocks are gapping in today's session ↗

March 14, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends.

Via Chartmill

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK

March 13, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Inflation Isn’t Going Away, But These Sectors Don’t Care ↗

March 13, 2025

The CPI and PPI releases this week came in more or less at estimates - nothing to alarm the talking heads, anyway. They show inflation slowing down but not receding.

Via Talk Markets

Topics ETFs Economy Stocks / Equities

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.